TRIMTECH Therapeutics raises $31M seed funding to advance targeted protein degradation pipeline for treatment of neurodegenerative diseases
- Oversubscribed financing led by Cambridge Innovation Capital and SV Health Investors’ Dementia Discovery Fund with M Ventures and Pfizer Ventures joining
- Investment will support further development of CNS penetrant therapeutics based on the Company’s TRIMTACTM aggregate-selective degraders